DCM
ARQT icon

Driehaus Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Driehaus Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Sell
878,426
-1,347,603
-61% -$31.4M 0.13% 211
2026
Q1 		$52.4M Sell
2,226,029
-336,416
-13% -$8.59M 0.39% 91
2025
Q4 		$74.4M Buy
2,562,445
+1,465,441
+134% +$37.5M 0.51% 61
2025
Q3 		$20.7M Buy
1,097,004
+11,050
+1% +$174K 0.15% 200
2025
Q2 		$15.2M Sell
1,085,954
-6,781
-0.6% -$95.1K 0.12% 204
2025
Q1 		$17.1M Sell
1,092,735
-4,034
-0.4% -$56.8K 0.16% 180
2024
Q4 		$15.3M Buy
+1,096,769
New +$12M 0.13% 201

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Driehaus Capital Management's ARQT Position: Q2 2026 in Review

Driehaus Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 61% in Q2 2026, selling an estimated $31.4M and leaving 878,426 shares worth $23M. The position accounts for 0.13% of the portfolio, ranked #211.

Driehaus Capital Management first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $74.4M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Driehaus Capital Management held 878,426 shares of Arcutis Biotherapeutics worth $23M as of Q2 2026.
  • Driehaus Capital Management sold 1,347,603 Arcutis Biotherapeutics shares in Q2 2026, an estimated $31.4M.
  • Arcutis Biotherapeutics made up 0.13% of Driehaus Capital Management's portfolio in Q2 2026, its #211 holding.
  • Driehaus Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Driehaus Capital Management's Arcutis Biotherapeutics position peaked at $74.4M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.